Entecavir Pediatric Study Should Proceed Alongside Animal Studies – Cmte.

Pediatric studies of Bristol-Myers Squibb's hepatitis B agent Baraclude (entecavir) should proceed concurrently with carcinogenicity studies in young animals, FDA's Antiviral Drugs Advisory Committee said